Revive Therapeutics Ltd
Revive Therapeutics Ltd is a biotechnology company focused on the development and commercialization of therapeutics for medical conditions, primarily in the pharmaceuticals and medical research sector.
Business. Revive Therapeutics Ltd (RVV.CD) is a biotechnology and medical research company operating within the healthcare sector. The firm focuses on pharmaceuticals and medical research activities. Specific details regarding operating segments, headquarters location, and primary exchange listings are not provided in the available data.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
Revive Therapeutics Ltd (RVV.CD) is a biotechnology and medical research company operating within the healthcare sector. The firm focuses on pharmaceuticals and medical research activities. Specific details regarding operating segments, headquarters location, and primary exchange listings are not provided in the available data.
Revive Therapeutics has a negative equity position of CAD -3,455,700 and a current ratio of 0.02, indicating severe liquidity constraints. The company's cash and equivalents amount to CAD 14,560, while its total liabilities exceed total assets by CAD 3,455,700. The negative return on assets of -53.71% highlights the company's inability to generate returns from its asset base.
The company's profitability is weak, with a net loss of CAD 11,011,320 and an operating loss of CAD 10,956,370. The return on equity of 3.19% is misleading due to the negative equity base, and the debt-to-equity ratio of -0.02 suggests minimal leverage but also reflects the company's negative net worth.
Revive Therapeutics does not disclose segment or geographic revenue breakdowns in the provided data, making it difficult to assess revenue concentration or geographic exposure. The company's operations are likely centered in North America, but this is inferred rather than stated.
The company's growth trajectory is uncertain, with no revenue growth data provided. The operating cash flow of CAD -767,660 and free cash flow of CAD -11,011,070 indicate ongoing cash burn. The company is not generating positive cash flows from operations, which is a concern for long-term sustainability.
The risk assessment indicates medium liquidity risk and low dilution risk. The company's negative net cash position after subtracting total debt is a key flag. The dilution risk is low, but the company's negative equity and cash flow position suggest a high risk of further dilution if it needs to raise additional capital.
Recent events include the company's continued financial losses and negative cash flows, as disclosed in the latest financial statements. No specific recent filings or transcripts are provided in the data, but the ongoing financial performance suggests the company is in a challenging position.
- Revive Therapeutics is experiencing significant financial losses and negative cash flows, indicating a lack of profitability and liquidity.
- The company's negative equity and high debt-to-equity ratio suggest a weak capital structure and potential insolvency risk.
- The absence of segment and geographic revenue data limits the ability to assess diversification and exposure.
- The company's growth trajectory is unclear, and it is not generating positive cash flows from operations.
- The risk assessment highlights medium liquidity risk and low dilution risk, but the company's financial position remains precarious.
Bull / Bear case
Generated · model-assistedIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- Return On Assetsnet_income / total_assets
- Revive Therapeutics Ltd Market data — financials · 2026-05-29